An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma by Iltzsche, F. et al.
 
 
 
 
 
Iltzsche, F. et al. (2017) An important role for Myb-MuvB and its target 
gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene, 36(1), 
pp. 110-121. (doi:10.1038/onc.2016.181)  
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/128138/ 
     
 
 
 
 
 
 
Deposited on: 13 September 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk33640 
	 1	
An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung 
adenocarcinoma 
 
 
Fabian Iltzsche1*, Katja Simon1*, Sabine Stopp1*, Grit Pattschull1*, Sven Francke1, Patrick 
Wolter1, Stefanie Hauser1, Daniel J. Murphy4, Paloma Garcia5, Andreas Rosenwald2,3 and 
Stefan Gaubatz1,2,6 
 
1Theodor Boveri Institute, Biocenter, University of Wuerzburg and 2Comprehensive Cancer 
Center Mainfranken, University of Wuerzburg, and 3Institute of Pathology, University of 
Wuerzburg, Wuerzburg, Germany; 4Institute of Cancer Sciences, University of Glasgow, and 
the CRUK Beatson Institute, Glasgow, UK; 5Institute of Biomedical Research, College of 
Medical and Dental Sciences, University of Birmingham, Birmingham, UK 
 
* equal contribution 
 
 
 
 
 
 
 
 
6Correspondence to:  
Stefan Gaubatz 
Phone (+49) 931-31-84138 
e-mail:stefan.gaubatz@biozentrum.uni-wuerzburg.de 
 
 
	 2	
ABSTRACT 
The conserved Myb-MuvB multiprotein complex plays an important role in transcriptional 
activation of mitotic genes. Myb-MuvB target genes are overexpressed in several different 
cancer types, and their elevated expression is associated with an advanced tumor state and 
a poor prognosis. This suggests that Myb-MuvB could contribute to tumorigenesis by 
mediating overexpression of mitotic genes. However, although Myb-MuvB has been 
extensively characterized biochemically, the requirement for Myb-MuvB in tumorigenesis in 
vivo has not been investigated. Here we demonstrate that Myb-MuvB is required for tumor 
formation in a mouse model of lung cancer driven by oncogenic K-RAS. We also identify a 
requirement for the mitotic kinesin KIF23, a key target gene of Myb-MuvB, in tumorigenesis. 
RNAi mediated depletion of KIF23 inhibited lung tumor formation in vivo, and induced 
apoptosis in lung cancer cell lines. Our results suggest that inhibition of KIF23 could be a 
strategy for treatment of lung cancer. 
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INTRODUCTION	
Mitotic proteins, such as spindle checkpoint proteins, key mitotic kinases and proteins 
required for cytokinesis, are frequently expressed at elevated levels in cancer cells. 
Increased expression of mitotic proteins is probably, at least in part, due to a higher fraction 
of proliferating cells in tumor tissue. However, many mitotic genes that are expressed at 
elevated levels in tumors are part of recently published chromosomal instability (CIN) 
signatures that predict the clinical outcome of various cancer types independent of the cell 
cycle score.1-3 Thus elevated expression of some of mitotic genes could play a causal role in 
tumor initiation or progression due to the abnormal execution of mitosis resulting in defects in 
chromosome segregation and aneuploidy. Mouse models have confirmed that the 
overexpression of mitotic proteins such as the spindle checkpoint protein MAD2 or the 
kinetochore protein HEC1 is sufficient to generate aneuploidy and to induce various tumors, 
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including lung adenomas.4,5 Several causes for the overexpression of mitotic genes in cancer 
cells have been identified. For example, inactivation of the retinoblastoma tumor suppressor 
protein leads to abnormal expression of MAD2 by E2F transcription factors.6 Similarly, the c-
MYC oncogene activates BUBR1 and MAD2 which in turn provoke a prometaphase delay 
that underlies the chromosomal missegregation induced by c-MYC.7  
Another key regulator of mitotic genes is the Myb-MuvB complex (reviewed in ref 8). MuvB is 
the core of an evolutionary conserved complex that regulates transcription during the cell 
cycle. Specifically, in quiescent cells MuvB, consisting of LIN9, LIN37, LIN52, LIN54 and 
RBBP4, associates with the p130 pocket protein and with E2F4 to form DREAM, which 
represses transcription.9,10 In contrast, in S phase, the interaction of the MuvB core with 
p130/E2F4 is lost and MuvB now binds to the B-MYB transcription factor to form the Myb-
MuvB complex (also called MMB).10-12 In late S-phase the transcription factor FoxM1 is also 
recruited into the complex.11 In contrast to DREAM, Myb-MuvB and MMB-FoxM1 act as 
transcriptional activators. Genome wide expression studies and chromatin 
immunoprecipitation (ChIP) assays revealed that MMB and FoxM1 regulate late cell cycle 
genes with functions in mitosis and cytokinesis such as PLK1, cyclin B or the kinesin KIF20A 
and that its inactivation results in mitotic defects.11-15 Interestingly, at least 10 out of 29 
mitotic genes included in the above-mentioned CIN signature of lung, brain and breast 
tumors are directly regulated by Myb-MuvB and FoxM1. Thus Myb-MuvB could promote 
tumorigenesis by activating the expression of critical mitotic genes.  
The relationship of Myb-MuvB to tumorigenesis is largely unknown and whether Myb-MuvB 
contributes to tumorigenesis in vivo has not directly been tested. Here we used a mouse 
model of lung cancer driven by oncogenic K-RAS and loss of p53 to investigate the 
requirement for Myb-MuvB during tumorigenesis in vivo. We find that Myb-MuvB is required 
for lung tumor development and that Myb-MuvB drives the expression of mitotic kinesins in 
lung cancer cells. Depletion of the mitotic kinesin KIF23, one of several genes regulated by 
Myb-MuvB, inhibits lung tumorigenesis and induces apoptosis in vitro and in vivo. Together 
these data establish a requirement for Myb-MuvB regulated genes for lung tumorigenesis. 
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RESULTS 
Myb-MuvB is required for lung tumor formation in vivo 
Little is known about the role of Myb-MuvB in cancer in vivo. To investigate whether Myb-
MuvB is involved in lung tumorigenesis, we used a well-characterized in vivo mouse model of 
NSCLC driven by oncogenic K-RAS and loss of p53 (ref.16). This mouse model is based on 
a conditional allele of oncogenic K-Ras (LSL-K-RasG12D) and conditional loss of function p53 
alleles (p53fl/fl) (Fig. 1A). Controlled activation of oncogenic K-RASG12D and loss of p53 in the 
lung is achieved by adenoviral or lentiviral Cre-recombinase, leading to the development of 
atypical adenomatous hyperplasias (AAH), adenomas, adenocarcinomas and invasive 
adenocarcinomas in the lungs within 13 weeks (Supplementary Figure S1).16,17 B-MYB 
expression was induced during this process as demonstrated by immunohistochemistry with 
an antibody that detects active B-MYB phosphorylated on threonine 487 by Cyclin A/CDK2 
(Fig. 1B).11,18 In contrast, in normal lung, no phospho-B-MYB expression could be detected. 
In tumors, phospho-B-MYB was expressed at higher levels in advanced stage 
adenocarcinomas (grade 3 and 4) compared to adenomas (grade 2) and low-grade atypical 
adenomatous hyperplasias (grade 1) (Fig. 1C, D). B-MYB (phospho-T487) 
immunohistochemistry in 11 human adenocarcinomas of the lung showed moderate to 
strong protein expression in all tumors (representative stainings shown in Fig. 1E), 
suggesting that it might have a role in lung tumorigenesis. Examination of previously 
published microarray data sets showed that high expression levels of B-MYB or of the Myb-
MuvB subunit LIN9 were associated with poor prognosis of lung adenocarcinoma patients 
(Fig. 1F). Furthermore, B-MYB protein expression was higher in lung cancer cell lines 
compared to non-transformed control cell lines (Fig. 1G). 
 
To directly address the relevance of these findings for tumor initiation and progression in 
vivo, we crossed LSL-K-RasG12D; p53fl/fl mice with mice with conditional loss of function alleles 
of B-MYB or the MuvB subunit LIN9 (B-Mybfl/fl or Lin9fl/fl) (Fig. 2A).15,19 Infection with Cre 
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vectors results in simultaneous activation of K-RasG12D, deletion of p53 and deletion of either 
B-Myb or Lin9 (Fig. 1A,2A). LSL-K-RasG12D; p53fl/fl mice with wildtype alleles of B-Myb and 
Lin9 served as respective controls. As additional controls, mice that retain one functional 
allele of B-Myb or Lin9 (Lin9fl/+ and B-Mybfl/+) after Cre-mediated recombination were used. At 
13 weeks after tumor initiation with equal biological titers of Cre-virus, B-Mybfl/fl and Lin9fl/fl 
mice showed significantly smaller tumors than control mice (Fig. 2B-D,F-H). In comparison to 
control mice, tumors in B-Mybfl/fl and Lin9fl/fl mice were also less advanced (Fig. 2E,I). 
Specifically, the tumors in B-Mybfl/fl  and Lin9fl/fl mice showed a lower tumor grade. Based on 
these data we conclude that Myb-MuvB is required for lung cancer driven by oncogenic K-
RAS in vivo. The relative tumor area in mice that retain one allele of B-Myb was comparable 
to that observed in control animals, suggesting that loss of one allele of B-Myb does not 
influence tumorigenesis. In contrast, relative tumor burden in heterozygous Lin9fl/fl mice was 
slightly increased compared to Lin9+/+ mice. Although the difference did not reach statistical 
significance, this might suggest that Lin9 can behave as an haploinsufficient tumor 
suppressor and as an oncogene in the same tumor type, similar to what has been observed 
for KLF4.20 
 
Next, to assess the efficiency of Cre-mediated recombination in tumors we determined the 
status of the B-Myb and Lin9 alleles by genomic PCR. In all tumors from LSL-K-RasG12D; 
p53fl/fl; B-Mybfl/fl  mice, a band corresponding to the unrecombined, floxed allele of B-Myb was 
detected, indicating incomplete inactivation of B-Myb (Fig. 3A). Similarly, tumors from LSL-K-
RasG12D; p53fl/fl; Lin9fl/fl mice retained unrecombined alleles of Lin9 (Fig. 3B).  To determine 
the expression of B-MYB in tumors from LSL-K-RasG12D; p53fl/fl; B-Mybfl/fl mice compared to 
control mice, we performed immunohistochemistry (Fig. 3C,D). We found lower expression of 
B-MYB in the majority of tumors from LSL-K-RasG12D; p53fl/fl; B-Mybfl/fl mice compared to 
controls (Fig. 3D). However, B-MYB expression was not completely lost in these tumors. 
LIN9 protein expression could not be investigated due to the lack of a suitable antibody for 
immunohistochemistry. Taken together, these results suggest that there is a strong selection 
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against the complete loss of LIN9 or B-MYB in tumors and that only tumors that escape the 
complete deletion of LIN9 or B-MYB are able to progress. The strong dependency on LIN9 
and B-MYB likely explains the difference in tumor formation in LSL-K-RasG12D;p53fl/fl ;Lin9fl/fl 
and LSL-K-RasG12D;p53fl/fl ;B-Mybfl/fl mice compared to control mice.  Incomplete deletion of 
tumor-essential genes in this in vivo model is consistent with previous reports using 
conditional Rac1-, CK1α- and JNK-deficient mice.21-23 
A requirement for Myb-MuvB in lung tumor cells in vitro 
To investigate the requirement for MuvB during proliferation of lung cancer cells in vitro, we 
next established primary cell lines from dissected lung adenocarcinomas from LSL-K-
RasG12D;p53fl/fl ;Lin9fl/fl mice (KPL1 and KPL2) and from control K-RasG12D;p53fl/fl mice with 
wildtype alleles of Lin9 (KP1 and KP2). We stably expressed the hormone-inducible CreERT2 
recombinase in KP and KPL cells. Addition of 4-OHT to KPL cells resulted in deletion of the 
remaining floxed allele of Lin9 and loss of protein expression, but had no effect on the Lin9 
wildtype allele or LIN9 protein expression in KP cells, as expected (Fig. 4A,B). Significantly, 
deletion of Lin9 strongly impaired the proliferation rate of KPL cells, while the addition of 4-
OHT had no effect on the proliferation of control cells (Fig. 4C,D). Microscopic examination 
showed that treatment with 4-OHT resulted in a high frequency of cellular abnormalities 
including multipolar mitosis, cells with multilobed nuclei and binucleated cells indicative of 
cytokinesis failure (Fig. 4E and Supplementary Figure S2). Thus loss of Lin9 in lung 
adenocarcinoma cells leads to nuclear abnormalities and a strong growth inhibition, providing 
a mechanistic explanation for the inhibitory effect of Lin9 deletion on lung tumorigenesis in 
vivo.  
 
Mitotic genes are targets of Myb-MuvB in lung cancer cells 
Previous microarray and ChIP experiments have identified mitotic genes such as the kinesin 
KIF23 (MKLP1), NUSAP1 and Survivin (BIRC5) as direct transcriptional targets of Myb-
MuvB.14,15,24 To analyze the regulation of mitotic gene expression by Myb-MuvB in lung 
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cancer cells and to determine the relationship with p53, we used a cell line derived from 
mouse lung adenocarcinomas with oncogenic K-RasG12D and a nonfunctional p53 allele 
which is blocked by a translational STOP cassette that can be removed by an inducible 
CreERT2 recombinase.25 The addition of 4-OHT to the cell culture medium activates CreERT2 
recombinase and results in re-expression of p53 (Fig. 5B).  Depletion of B-MYB or LIN9 in 
KPR8 cells (before p53 restoration) by RNA interference reduced the expression of six 
mitotic kinesins as well as four other Myb-MuvB genes (CENPF, PLK1, BIRC5 and NUSAP1) 
with functions in mitosis (Fig. 5A).  
Restoration of the p53 allele by addition of 4-OHT induced p53 protein expression and 
strongly activated p21CIP1, a cyclin-dependent kinase inhibitor and a well-known p53-target 
gene (Fig. 5C). In contrast, mitotic genes were downregulated after p53-restoration, 
indicating that the Myb-MuvB-dependent genes are repressed after restoration of p53 (Fig. 
5C). p53 restoration induced association of p130 with MuvB while it displaced B-MYB from 
the MuvB core, indicating that activation of p53 promotes formation of the repressive DREAM 
complex (Fig. 5D). Consistent with these findings, chromatin immunoprecipitation (ChIP) 
assays showed that binding of B-MYB to the promoters of NUSAP1 and CENP-F was 
strongly reduced after p53 restoration while binding of p130 was induced (Fig. 5E). These 
changes correlate with reduced expression of NUSAP1 and CENP-F after p53-restoration. 
RNAi mediated depletion of Myb-MuvB subunits LIN9 and B-MYB and ChIP experiments in 
the human lung adenocarcinoma cell line H23 confirmed that Myb-MuvB is required to drive 
overexpression of mitotic genes (Supplementary Figure S3). Together these data suggest 
that Myb-MuvB drives expression of mitotic genes in lung carcinoma cells in the absence of 
functional p53. Consistent with this notion, immunohistochemistry showed that Nusap1 is 
expressed in murine lung adenocarcinomas and that its expression correlated with tumor 
grade (Supplementary Figure S4). Furthermore, there is a high correlation between the 
expression of B-MYB and the Myb-MuvB target gene Nusap1 in individual lung 
adenocarcinomas in vivo (Fig. 5F) 
 
	 8	
The Myb-MuvB regulated mitotic kinesin KIF23 is required for proliferation of lung cancer 
cells and for tumor formation in vivo 
Although these observations suggest that Myb-MuvB might be a therapeutic target for the 
treatment of lung cancer, inhibiting its function with small molecules will be difficult to achieve 
as no enzymatic activities have been identified in the complex. Mitotic kinesins are targets of 
Myb-MuvB in lung cancer cells (Fig.5 and Supplementary Figure S3). They have emerged as 
potential new drug targets given their association with chromosomal instability signatures 
and the correlation of their expression with poor clinical outcome.26,27 We therefore next 
selected the Myb-MuvB regulated mitotic kinesin KIF23 (MKLP1) for a more detailed 
characterization.24 KIF23, a kinesin of the kinesin-6 family, is a subunit of the centralspindlin 
complex that is critical for formation of the central spindle.28 To assess the therapeutic effect 
of inhibiting KIF23, we used a multifunctional lentiviral vector to establish several stable lung 
cancer cell lines that express doxycycline-inducible small hairpin RNAs (shRNAs) directed at 
KIF23 (Fig. 6A). Because upon addition of doxycycline RFP is co-expressed together with 
the shRNA, we first measured the expression of RFP after treatment with different 
concentrations of doxycycline to determine the response in the different cell lines. In absence 
of doxycycline, the cells were RFP-negative, indicating that the system is tightly regulated 
(Supplementary Figure S5, S6). Addition of doxycycline for three days resulted in a dose-
dependent induction of RFP-fluorescence. After addition of 1 µg/ml doxycycline, more than 
90% of cells expressed RFP. Treatment with doxycycline resulted in a dose-dependent 
knockdown of KIF23 protein in the four cell lines (Fig. 6B). Next we investigated the effect of 
KIF23 depletion on growth of lung cancer lines by treatment of the stable cell lines with 
different concentrations of doxycycline and by assaying cell number using crystal violet 
staining. Proliferation of all four cell lines was inhibited by KIF23 depletion (Fig. 6C, 
Supplementary Figure S7A). The two cell lines H23 and HOP92 were most sensitive to 
KIF23 depletion and their growth was strongly inhibited even at low concentrations of 
doxycycline (Fig. 6C). As determined by FACS, the sub G1 population, indicative of 
degraded DNA, a hallmark of apoptosis, was  also strongly  increased in these two cell lines 
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following KIF23 depletion (Fig. 6D). Microscopic examination demonstrated that depletion of 
KIF23 increased the number of cancer cells with abnormal nuclei such as binucleated cells, 
multinucleated cells and giant multinucleated cells (Fig. 6E, Supplementary Figure S7B). In 
summary, our results indicate that depletion of KIF23 induces mitotic catastrophe as 
characterized by the formation of giant multinucleated cells followed by apoptotic cell death.  
To test whether depletion of KIF23 can inhibit lung tumorigenesis in vivo, we used the K-RAS 
dependent NSCLC mouse model described above. For this purpose we created a 
bifunctional lentivirus that expresses Cre recombinase and in addition a shRNA to knock 
down KIF23 (Fig. 7A). The shRNA is identical to the one used in human tumor cells due to 
conservation of the target sequence. Furthermore the KIF23-specific shRNA resulted in 
efficient knockdown of the KIF23 mRNA in murine NIH-3T3 cells (Supplementary Figure 7C). 
LSL-K-RasG12D;p53fl/fl mice were infected with the bifunctional lentivirus to induce lung 
adenocarcinomas and simultaneously deplete KIF23. In parallel, LSL-K-RasG12D;p53fl/fl mice 
were infected with a lentivirus expressing Cre recombinase and a control-shRNA directed at 
luciferase. Mice were sacrificed 14 weeks after tumor induction and lung tumors were 
analyzed histologically. Depletion of KIF23 significantly impaired lung tumor development 
indicating a requirement for KIF23 in K-RAS-driven NSCLC in vivo (Fig. 7B,C,D).  
 
DISCUSSION	
 
Myb-MuvB has been identified in previous studies as a master regulator of mitotic gene 
expression (for review see ref. 11). Myb-MuvB target genes and B-MYB itself are frequently 
expressed at elevated levels in tumors and their deregulation is associated with more 
advanced stages of the disease.1,2 However, whether Myb-MuvB contributes to cancer in 
vivo has not been analyzed. To address this issue, we have used a mouse model of lung 
adenocarcinoma induced by oncogenic K-RAS and loss of p53. We find that deletion of B-
Myb or of Lin9, a core subunit of MuvB, inhibits tumor formation in this model. 
Mechanistically, we provide evidence that proliferation of lung cancer cells strongly depends 
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on Myb-MuvB, which acts to activate mitotic genes in these cells. We also show that 
transcriptional activation by Myb-MuvB is antagonized by p53, corroborating earlier studies of 
indirect repression of mitotic genes by p53 through formation of DREAM.29-31 Induction of p53 
results in displacement of B-MYB from Myb-MuvB and in formation of the repressive 
DREAM-p130 complex. Collectively, this suggests that Myb-MuvB contributes to the 
upregulation of G2/M phase specific genes in p53-negative cells.  
On the basis of our findings one might consider Myb-MuvB as a therapeutic target for the 
treatment of lung cancer. However, because no enzymes have so far been identified in the 
Myb-MuvB complex, inhibiting its function with small molecules will be difficult to achieve. A 
promising new strategy that has recently emerged is degradation of multidomain scaffold 
proteins by ligand-induced protein degradation using bifunctional ligands.32 Here one part of 
the ligand is specific to the target protein while the other part recruits a cellular E3 ligase that 
mediates proteasomal degradation of the target. However, the complete inhibition of Myb-
MuvB might be problematic, given that the deletion of B-Myb or Lin9 in mice is known to 
result in lethality.15,33 Limited inhibition of Myb-MuvB might provide a therapeutic window to 
treat lung adenocarcinomas. An alternative approach would be to target the downstream 
targets of Myb-MuvB such as the mitotic kinesin KIF23, which was investigated in this study.  
Kinesins are ATP-dependent motor proteins that regulate the dynamic properties of 
microtubules.26,34 Of the 45 kinesins in the human genome, at least 16 have been implicated 
in coordinating mitosis and cytokinesis. They are responsible for the formation and function 
of the mitotic spindle, chromosome segregation and cytokinesis. Due to their specialized 
functions in mitosis, mitotic kinesin inhibition might produce fewer side effects compared to 
microtubule targeting agents currently used in the clinic. 
KIF23 belongs to the kinesin-6 family, whose members have non-redundant roles in 
cytokinesis.26,35 Expression of KIF23 has been shown to be upregulated in glioma and non-
small cell lung cancer compared to normal tissues.36,37 In addition, KIF23 is associated with a 
signature of 100 genes whose elevated expression was associated with chromosomal 
instability and a poor prognosis across 6 different cancer types including breast cancer and 
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colon cancer.2 It is possible that the overexpression of KIF23 leads to defects in 
chromosome segregation, thereby contributing to chromosomal instability (CIN) and 
aneuploidy, which is tightly associated with tumorigenesis.38 Although these observations 
suggest that KIF23 plays a role in tumorigenesis, it has not yet been investigated whether it 
is required for tumor formation in vivo. Here we demonstrate that depletion of KIF23 inhibited 
lung tumor formation in vivo, similar to what is seen with deletion of Myb-MuvB. In vitro, the 
depletion of KIF23 in lung cancer cell lines showed strong anti-proliferative activity, which 
was accompanied by apoptosis in a subset of cell lines. Cell death in response to KIF23 
downregulation could contribute to the reduction in tumor size in vivo. Downregulation of 
KIF23 can inhibit proliferation of glioma cells, suggesting that KIF23 may be therapeutic 
target for additional tumor types in addition to lung cancer.37 In future work it will be important 
to assess the therapeutic potential of inhibiting KIF23 in already established tumors and to 
asses the toxicities for non-transformed cells. 
 
 
MATERIALS AND METHODS 
Mice 
All animals were maintained on a C57BL/6 background. LSL-K-RASG12D, conditional p53, 
conditional B-Myb and conditional Lin9 knockout mice have been described.39,15,19,40 LSL-K-
RASG12D and conditional p53 mice were obtained from the NCI Mouse Repository, Bethesda, 
Maryland. Tumors were initiated in 6 to 9 weeks old male and female mice by nasal 
instillation of calcium phosphate precipitated adenovirus-Cre (Gene Transfer Vector Core, 
University of Iowa; 105 PFU per mouse) or by intratracheal infection of mice with a lentiviral 
vector expressing Cre-recombinase (106 lentiviruses per mouse) as described previously.17,41 
Sample size was based on comparable studies in the literature. To deliver the virus, mice 
were anesthetized with Ketamin/Xylazin. For infection with the Cre-shLuc (control) or Cre-
shKIF23 lentivirus, LSL-K-RASG12D;p53fl/fl mice were randomly allocated to 2 groups. All 
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animal experiments were carried out according to protocols that were approved by an 
institutional committee (Tierschutzkommission der Regierung von Unterfranken). 
 
Genotyping of mice, primary tumors and cell lines 
The status of the K-Ras, B-Myb and Lin9 alleles in tumors and tumor cell lines was analyzed 
by PCR with previously described primers.15,19,39 To determine the recombination of Lin9 and 
B-Myb in primary tumors, genomic DNA was isolated by scraping the tumor material with 
forceps into 1 ml pure Xylene. Samples were centrifuged for 5 minutes at full speed in a 
tabletop centrifuge at RT and washed twice with 1 ml absolute ethanol. Genomic DNA from 
the obtained pellet was further processed and genotyped. 
 
Lentivirus production and titer determination 
Lentviruses were produced as described previously.42 To determine the biological lentiviral 
titer, we first generated a Cre-reporter cell line by stably transfecting NIH-3T3 cells with the 
GFP-reporter plasmid pZ/EG.43 For titer determination, the Z/EG reporter cell line (which 
expresses GFP after Cre-mediated recombination) was infected with serially diluted 
lentivirus. The fraction of GFP-positive cells was determined by FACS.  
 
Cell culture 
H23, H460, HOP62, HOP92, H226, H522, H358, H441 and A549 cells were cultured in RPMI 
containing 10% FCS (Invitrogen).  BJ, WI38, and KPR8 cells were cultured in DMEM 
(Invitrogen) containing 10% FCS (Invitrogen). Human cell lines have been authenticated by 
the multiplex human cell line authentication test (MCA, Multiplexion). To re-activate p53 in 
KPR8 cells, cells were treated with 500 nM 4-hydroxytamoxifen (Sigma) for the indicated 
time.25  
 
Histopathology and immunohistochemistry 
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Mouse lung tissues were fixed in 4% paraformaldehyde in PBS, embedded in paraffin and 
sectioned. Sections were deparaffinised, rehydrated and stained with hematoxylin and eosin 
or processed for immunohistochemistry staining. Tumor grading was performed in a blinded 
manner in accordance to the literature.17 For immunohistochemistry, sections were incubated 
for 15 minutes with 3% H2O2 to quench endogenous peroxidase. Antigen retrieval was 
performed in 10 mM sodium citrate buffer (pH 6.0) by boiling in a microwave for 15 minutes. 
Slides were blocked with 3% BSA in PBS and incubated with relevant primary antibodies 
overnight at 4°C. Secondary antibody was applied to sections at 1:200, incubated for 60 min 
at RT and developed in diaminobenzidine (DAB). Human adenocarcinomas of the lung were 
stained immunohistochemically using the anti-B-MYB (phospho T487) antibody (clone 
EPR2204Y, rabbit monoclonal, 1:100 dilution, Abcam) following antigen retrieval with 
pressure cooking (citric acid pH 6.0). 
 
Isolation of tumor cell lines 
KP and KPL cell lines were derived by enzymatic and mechanical dissociation of individual 
lung tumors as described previously.44 Briefly, tumors were dissected under aseptic 
conditions and minced with sterile razor blades in 2 ml Trypsin/EDTA (0.25%) in a 100 mm 
cell culture dish. After 30 minutes of trypsinisation at 37°C, the reaction was stopped with 10 
ml fresh media. Tissue was broken up by pipetting and the cell suspension was cultured in 
media supplemented with Mouse FibrOut™ 9 (CHI Scientific). Cells were cultured until 
confluency was reached, genotyped and stored for further processing.  
 
Antibodies 
The following primary antibodies were used: LIN9: ab62329 (Abcam); B-MYB: LX015.1 (kind 
gift from Roger Watson).45 p-B-MYB (T487): ab76009 (Abcam). NUSAP1: kind gift from 
Geert Carmeliet.46 p130: sc-317 (Santa Cruz Biotechnology). KIF23: sc-22793 (Santa Cruz 
Biotechnology); p53 (Pab240; sc-99) (Santa Cruz Biotechnology); Tubulin: clone B-5-1-2 
(Sigma). Actin: sc-47778 (Santa Cruz). 
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Immunoprecipitation and immunoblotting  
Cells were lysed in TNN [50 mM Tris (pH 7.5), 120 mM NaCl, 5 mM EDTA, 0.5% NP40, 10 
mM Na4P2O7, 2 mM Na3VO4, 100 mM NaF, 10 mg/mL phenylmethylsulfonyl fluoride, 
protease inhibitors (Sigma)]. Whole cell lysates were immunoprecipitated with antibodies 
over night at 4 °C, bound to Protein-G-Sepharose for 2 h and washed 5 times with TNN lysis 
buffer. Proteins were separated by SDS-PAGE, transferred to PVDF membrane and 
detected by immunoblotting. 
 
Chromatin Immunoprecipitation (ChIP) 
Cells were cross-linked with 1% formaldehyde for 10 min at room temperature. The reaction 
was stopped by adding 125 mM glycine. Cells were lysed for 10 min in lysis buffer [5 mM 
PIPES (pH 8.0), 85 mM KCl, 0.5% NP40, protease inhibitors (Sigma)]. Nuclei were lysed in 
nuclei lysis buffer [50 mM Tris (pH 8.1), 10 mM EDTA, 1% SDS, protease inhibitors (Sigma)]. 
Chromatin was sonicated to an approximate length of 250 to 500 bp, diluted 1:10 with 
dilution buffer [0.01% SDS, 1.1% Triton, 1.2 mM EDTA, 16.7 mM Tris (pH 8.2), 167 mM 
NaCl, protease inhibitors (Sigma)] and used for immunoprecipitation overnight. 
Immmunoprecipitates were collected with protein G–dynabeads (Life Technologies) for 1 h 
(blocked with 1 mg/mL BSA and 0.3 mg/ml ssDNA). Beads were washed seven times with 
LiCl washing buffer [0.25 mM LiCl, 0.5% NP40, 0.5% sodium deoxycholate, 1 mM EDTA, 10 
mM Tris (pH 8.0), protease inhibitors (Sigma)] and eluted with elution buffer [50 mM Tris (pH 
8.0), 1% SDS, 10 mM EDTA]. The cross-link was reversed overnight with 0.2 mM NaCl at 
65°C. After proteinase K incubation for 2 h at 55°C, chromatin was purified using Qiagen 
DNA purification spin columns and eluted in 50 µl. Chromatin (1 µl) was used as template for 
quantitative real-time PCR.  
 
RNAi 
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The siRNAs targeting human and murine LIN9 and B-MYB have been described before.12-
14,29 Double stranded RNA was purchased from MWG. siRNAs were transfected in a final 
concentration of 50 nM using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's protocol. 
For inducible expression of a KIF23 shRNA in lung cancer cells, the lentiviral pINDUCER10 
vector was first modified by replacing the puromycin resistance gene for a blasticidin 
resistance gene.47  Next, a mir30 based shRNA specific for KIF23 was cloned into the vector. 
The targeting sequence for KIF23 is: 5' CCCAGAGTTTGCAGATATGATA 3'.  Lung cancer 
cell lines stably expressing KIF23 specific shRNA were generated by lentiviral infection and 
selection with blasticidin.  
 
RNA isolation, reverse transcription and quantitative real-time PCR 
Total RNA was isolated with Total RNA Isolation Reagent (Thermo Scientific). 1 µg RNA was 
transcribed using 125 units MMuLv (Thermo Scientific). Quantitative real–time PCR reagents 
were from Thermo Scientific and real-time PCR was performed using the Mx3000 
(Stratagene) detection system. Expression differences were calculated as described 
before.10  
 
Statistical analysis 
Statistical analyses were performed using Prism 5 (GraphPad Software). Statistical 
significance was determined using Student’s t test. P values <0.05 were considered 
statistically significant. Survival analyses for human lung adenocarcinoma patients were 
computed using an online tool (http://kmplot.com). Log-rank was automatically computed.48 
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FIGURE LEGENDS 
 
Figure 1: Expression of the Myb-MuvB subunit B-MYB in lung adenocarcimomas.  A) 
Cre-mediated mouse lung cancer model. Infection of LSL-K-RasG12D;p53fl/fl mice with Cre-
expressing Ade-Cre or Lenti-Cre vectors initiates lung tumorigenesis by activation of 
oncogenic K-RASG12D and loss of p53 (p53∆/∆). B) Immunohistochemistry staining of p-B-MYB 
(phospho T487) in lung tumors and adjacent normal lung tissue from LSL-KrasG12D;p53fl/fl 
mice 13 weeks after tumor initiation. Bar: 50 µm. C) Expression of p-B-MYB (phospho T487) 
in grade 1 and grade 3 murine K-RasG12;p53∆/∆ lung tumors as determined by 
immunohistochemistry. Left: Magnification 5 x. Bar: 150 µm; Right: Magnification: 20 x. Bar: 
50 µm D) Quantification of p-B-MYB (phospho T487) and expression in murine lung tumors 
from grade 1 (atypical adenomous hyperplasia; AAH) to grade 4 invasive adenocarcinoma 
(see Supplementary Figure S1). E) Expression of p-B-MYB (phospho T487) in human lung 
adenocarcinoma was determined by immunohistochemistry. Magnification: 100 x (left), 200 x 
(middle), 400 x (right). F) Kaplan-Meier curves correlating lung adenocarcinoma patients' 
survival with B-MYB and LIN9 expression. G) B-MYB expression in a panel of human lung 
cancer cell lines and two control cell lines (BJ and WI38) was analyzed by immunoblotting. 
Actin was used as a loading control.  
 
Figure 2: Requirement for B-MYB and LIN9 in a mouse model for lung cancer.  A) 
Scheme of the conditional alleles of Lin9 and B-Myb. B) -E) LSL-KrasG12D;p53fl/fl;B-Myb+/+ 
(n=14); KrasG12D;p53fl/fl;B-Mybfl/+ (n=13) and KrasG12D;p53fl/fl;B-Mybfl/fl (n=15) mice were 
infected with Lenti-Cre. Mice were sacrificed 13 weeks after tumor initiation. B) Example lung 
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images C) Representative histological section stained with haematoxylin and eosin. D) 
Quantification of tumor area to total lung area. Each symbol represents the analysis of an 
individual animal. Individual tumor area was obtained by measuring all tumors from 2 
sections from each mouse. The black bar indicates the mean. The error bars represent SEM.  
E) Distribution of tumor grades (n=766 tumors LSL-KrasG12D;p53fl/fl;B-Myb+/+; n=652 tumors 
LSL-KrasG12D;p53fl/fl;B-Mybfl/fl). The error bars represent SEM. F)-I) LSL-KrasG12D;p53fl/fl;Lin9+/+ 
(n=10); KrasG12D;p53fl/fl;Lin9fl/+ (n=10) and KrasG12D;p53fl/fl;Lin9fl/fl (n=10) mice were infected 
with Ade-Cre. Mice were sacrificed 13 weeks after tumor initiation.  F) Representative lung 
images G) Representative histological sections stained with haematoxylin and eosin. H) 
Quantification of tumor area to total lung area. Each symbol represents the analysis of an 
individual animal. Individual tumor area was obtained by measuring all tumors from 2 
sections from each mouse. The black bar indicates the mean. The error bars represent SEM.   
I) Distribution of tumor grades. (n=708 tumors LSL-KrasG12D;p53fl/fl; Lin9+/+; n=647 tumors 
LSL-KrasG12D;p53fl/fl; Lin9fl/fl). The error bars represent SEM. For all panels: *, ** or *** 
indicates that the differences were statistically significant; *p<0.05; **p<0.001 , *** p<0.0001 ; 
Student's t-test; two-sided. 
 
Figure 3: Incomplete recombination of B-Myb and Lin9 in lung tumors. A) Genomic 
PCR of B-Myb and K-Ras alleles in tumors dissected from LSL-K-RasG12D;p53fl/fl;B-Mybfl/fl 
mice showing retention of the B-Mybfl allele in tumors. fl: un-recombined B-Myb allele; ∆fl: 
recombined B-Myb allele. LSL: non-recombined K-RASG12D allele. ∆LSL: recombined K-
RasG12D allele *:denotes a background band. B) PCR of Lin9 and K-Ras alleles in tumors 
dissected from LSL-K-RasG12D;p53fl/fl;Lin9fl/fl mice showing retention of the Lin9fl allele. fl: un-
recombined Lin9 allele; ∆fl: recombined Lin9 allele. LSL: non-recombined K-RASG12D allele. 
∆LSL: recombined K-RasG12D allele *:denotes a background band. D) Immunohistochemistry 
staining of lung sections from LSL-K-RasG12D;p53fl/fl;B-Mybfl/fl mice with an anti-p-B-MYB  
(phospho T487) antibody demonstrates that tumors express B-MYB. Left: 10 x, bar 150 µm; 
right: 40 x, bar: 50 µm. D) The fraction of tumors expressing low (<10% of cells positive for 
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B-MYB), medium 1(0-30 % of cells positive for B-MYB) and high (> 30 % of cells positive for 
B-MYB) levels of phospho-B-MYB in mice of the indicated genotypes was determined by 
immunohistochemistry.For each genotype, tumors from 4 different mice were analyzed. 
Number of tumors analyzed: B-Myb+/+: 233; B-Mybfl/+: 284; B-Mybfl/fl: 108.  
 
Figure 4: Adenocarcinoma-derived cell lines are sensitive to the loss of LIN9. A) KP 
cells (derived from dissected tumors from LSL-KrasG12D;p53fl/fl;Lin9+/+ mice) and KPL cells 
(from tumors from LSL-KrasG12D;p53fl/fl;Lin9fl/fl mice) were stably transfected with hormone 
inducible CreERT2 recombinase. Treatment with 10 nM 4-OHT results in deletion of the 
remaining Lin9 allele in KPL cells as determined by genomic PCR. B) LIN9 protein levels in 
control treated and 4-OHT treated KP and KPL cells were determined by 
immunoprecipitation followed by immunoblotting. C) and D) Impaired proliferation of lung 
cancer cells upon deletion of Lin9. KP and KPL cells were seeded at low density and treated 
with 10 nm 4-OHT or with solvent for 10 days. Cells were fixed and stained with crystal violet. 
C) Representative example from 3 replicates. D) Growth curves over 10 days. Mean of three 
independent replicates. Error bars represent standard deviation. **p<0.001 , *** p<0.0001 ; 
Student's t-test; two-sided. E) Quantification of mitotic defects in KP and KPL cells upon 
deletion of Lin9 by treatment with 4-OHT for 3 days.  Per condition, 500 to 800 cells were 
counted. For another time-point and for examples of mitotic defects see Supplementary 
Figure S2.  
 
Figure 5: Gene regulation by Myb-MuvB in lung cancer cells. A) B-MYB or LIN9 were 
depleted by RNAi in murine lung cancer KPR8 cells. Expression of the indicated mitotic 
genes was analyzed by RT-qPCR. Two independent experiments were analyzed in triplicate 
by qPCR. One representative experiment is shown. B) Restoration of p53 in KPR8 lung 
adenocarcinoma cells is achieved by addition of 4-OHT, which activates Cre to remove a 
STOP cassette. C) Mitotic genes are downregulated after p53 re-activation in KPR8 cells as 
determined by RT-qPCR. p53 protein and the p53-target gene p21 were induced after p53-
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restoration, as expected. Two independent experiments were analyzed in triplicate by qPCR. 
One representative experiment is shown. D) Formation of the repressive DREAM complex 
and replacement of B-MYB from MuvB after restoration of p53. LIN9 was immunoprecipitated 
before and after p53-restoration and bound B-MYB and p130 were analyzed by 
immunoblotting. E) ChIP assay to analyze binding of B-MYB and p130 to the NUSAP1 and 
CENP-F promoters before and after restoration of p53 by 4-OHT. Binding to the indicated 
promoters was analyzed by RT-qPCR. Two independent ChIP assay were analyzed in 
triplicate by qPCR. One representative experiment shown. F) B-MYB and Nusap1 are 
coexpressed in murine lung adenocarcinomas from K-RASG12D; p53∆/∆ mice as determined by 
immunohistochemistry. The table on the right shows the number of tumors with or without B-
MYB and NUSAP1 expression.  p-value <0.0001, Chi-square, two sided. Bar: 100 µm.  
 
Figure 6: The Muyb-MuvB regulated mitotic kinesin KIF23 is required for proliferation 
of lung cancer cells. A) Scheme of the pINDUCER vector for doxycycline-inducible 
expression of the KIF23 shRNA. B) Stable lung cancer cell lines expressing an inducible 
KI23-specific shRNA were generated. Knockdown of KIF23 after induction of the shRNA with 
the indicated concentrations of doxycycline was determined by immunoblotting. Actin was 
used as a loading control. C) Growth of lung cancer cell lines stably expressing the KIF23-
specific shRNAs in presence of the indicated concentrations of doxycycline was analyzed 
over 8 days. Mean of three independent replicates. Error bars represent standard deviation. 
Significance levels versus control (for reasons of clarity are only indicated for day 8). 
*p<0.05; **p<0.001 , *** p<0.0001 ; Student's t-test; two-sided. D) The fraction of apoptotic 
subG1 cells after depletion of KIF23 was determined by FACS. E) Quantification of cells with 
abnormal nuclei upon depletion of KIF23. Per condition, more than 300 cells were counted. 
See also Supplementary Figure S7B.  
 
Figure 7: A requirement for KIF23 in lung cancer.  
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A) Scheme of the bifunctional lentivirus encoding for a mir30 based KIF23-specific shRNA 
and Cre-recombinase B)-C) LSL-KRasG12D;p53fl/fl  mice were infected with a bifunctional 
lentivirus encoding Cre and a control shRNA (n=7) or with a virus encoding Cre and a 
shRNA specific for KIF23 (n= 8). B) Representative lung images C) Representative 
histological section stained with haematoxylin and eosin. D) Quantification of tumor to total 
lung area. The error bars represent SEM. * indicates that the differences were statistically 
significant; p<0.05; Student's t-test; two-sided. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure S1: Tumor grades in RasG12D; p53∆/∆ lung tumors. Representative 
histology (H&E) of K-RasG12D; p53∆/∆ lung tumors 13 weeks after tumor initiation. Grade I: 
atypical adenomatous hyperplasias (AAH); Grade II: adenomas; Grade III: adenocarcinomas; 
Grade IV: invasive adenocarcinomas. Size bar: 50 µm. 
 
Supplementary Figure S2: Deletion of Lin9 results in multiple mitotic defects. A) KPL 
cells were treated with 10nm 4-OHT for 72 hours and cells were fixed and stained with an 
anti-tubulin antibody (green). DNA was counterstained with Hoechst 33548 (blue). Deletion 
of Lin9 resulted in binucleated cells, multipolar spindles and cells with large multilobed nuclei. 
Size bar: 25 µm. B) Quantification of mitotic defects in KP and KPL cells upon deletion of 
Lin9 by treatment with 4-OHT for 6 days.  
 
Supplementary Figure S3: Myb-MuvB-dependent expression of mitotic kinesins in the 
human lung cancer cell line H23. A) B-MYB or LIN9 were depleted by RNAi in H23 cells. 
Expression of the indicated kinesins was analyzed by RT-qPCR. B) ChIP assay 
demonstrating direct binding of B-MYB and LIN9 to the promoters of kinesins but not to the 
GAPDH promoter in H23 cells. IgG was used as a control. 
 
Supplementary Figure S4: NUSAP1 expression in lung adenocarcinomas. A) 
Immunohistochemistry staining of NUSAP1 in lung tumors and adjacent normal lung tissue 
from LSL-KrasG12D;p53fl/fl mice 13 weeks after tumor initiation. Bar: 50 µm. B) NUSAP 
expression correlates with tumor grade. Expression of NUSAP1 in grade 1 and grade 3 
murine K-RasG12; p53∆/∆ lung tumors was determined by immunohistochemistry. Left: 
Magnification 5 x. Bar: 150 µm; Right: Magnification: 20 x. Bar: 50 µm C) Quantification of 
NUSAP1 and expression in murine lung tumors relative to tumor grade from grade 1 (see 
Supplemental Figure S1).  
	 2	
 
Supplementary Figure S5: Inducible knockdown of KIF23. Lung cancer cell lines stably 
expressing an inducible KIF23-specific shRNA together with RFP were treated with the 
indicated concentrations of doxycycline. The expression of RFP was determined by 
microscopy.  
 
Supplementary Figure S6: Inducible knockdown of KIF23. Lung cancer cell lines stably 
expressing an inducible KIF23-specific shRNA together with RFP were treated with the 
indicated concentrations of doxycycline. The expression of RFP was determined by FACS.  
 
Supplementary Figure S7: KIF23 is required for proliferation of lung cancer cell lines. 
A) The indicated NSCLC cell lines (non-shRNA transfected controls or expressing the KIF23-
specific shRNAs) were cultured for 8 days with the indicated concentrations of doxycycline. 
Colonies were stained with crystal violet. B) Abnormal nuclei after depletion of KIF23. Bar: 25 
µm. The indicated cell lines stably expressing the KIF23-specific shRNA were treated with 
doxycycline for 4 days. Cells were fixed and stained with an anti-tubulin antibody (green). 
Nuclei were stained with Hoechst 33548 (blue). Bar: 25 µm. C) Knockdown of KIF23 in 
mouse NIH-3T3 cells by the KIF23-specific shRNA was verified by RT-qPCR. 
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